Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001
Symbol
LYEL on Nasdaq
Shares outstanding
19,139,684
Price per share
$24.03
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
11,391,805
Total reported value
$349,891,420
% of total 13F portfolios
0%
Share change
+239,937
Value change
+$8,387,255
Number of holders
67
Price from insider filings
$24.03
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARCH Venture Fund IX, L.P. 13% $44,807,053 2,759,072 ARCH Venture Fund IX, L.P. 30 Sep 2025
Innovative Cellular Therapeutics Holdings Ltd 9.8% $30,855,810 1,900,000 Innovative Cellular Therapeutics Holdings Ltd 06 Nov 2025
Foresite Capital Fund IV, L.P. 7.6% $23,622,818 1,454,616 James B. Tananbaum 30 Sep 2025
Gates Frontier, LLC 5.6% $10,628,242 1,040,964 Gates Frontier, LLC 25 Jul 2025
NEWTON (PTC) Ltd 3.9% $12,256,220 754,698 Newton (PTC) Limited 30 Sep 2025

As of 31 Dec 2025, 67 institutional investors reported holding 11,391,805 shares of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL). This represents 60% of the company’s total 19,139,684 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARCH Venture Management, LLC 14% 2,759,072 0% 13% $84,924,236
GSK plc 7.9% 1,512,659 0% 5.8% $46,559,644
MWG Caph Ltd 5.3% 1,008,116 0% 43% $31,029,810
VANGUARD GROUP INC 4.3% 826,430 +6.1% 0% $25,437,516
Foresite Capital Management IV, LLC 4.2% 800,399 0% 11% $24,636,281
Orland Properties Ltd 3.9% 754,698 0% 4.3% $23,229,604
Almitas Capital LLC 3% 577,807 0% 3.9% $17,784,899
Foresite Capital Management V, LLC 2.5% 477,078 0% 8.9% $14,684,461
venBio Partners LLC 1.8% 337,697 -29% 4.8% $10,394,314
CITADEL ADVISORS LLC 1.7% 324,701 -4.4% 0.01% $9,994,297
Alphabet Inc. 1.5% 293,256 0% 0.35% $9,026,420
BlackRock, Inc. 0.95% 181,837 +2.8% 0% $5,596,944
GEODE CAPITAL MANAGEMENT, LLC 0.85% 162,997 +25% 0% $5,019,879
HSG Holding Ltd 0.8% 152,299 0% 0.24% $3,935,406
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.79% 151,016 +835% 0.01% $4,648,272
Invesco Ltd. 0.52% 98,649 0% $3,036,416
GOLDMAN SACHS GROUP INC 0.51% 96,675 0% $2,975,657
MIC Capital Management UK LLP 0.45% 87,028 0% 0.61% $2,678,722
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.45% 85,423 +7.4% 0% $2,629,320
RBF Capital, LLC 0.39% 74,585 -22% 0.1% $2,295,726
MARSHALL WACE, LLP 0.38% 73,315 0% $2,256,635
MILLENNIUM MANAGEMENT LLC 0.31% 58,651 -53% 0% $1,805,278
STATE STREET CORP 0.27% 51,472 +53% 0% $1,584,308
MORGAN STANLEY 0.22% 42,949 +16% 0% $1,321,971
JOHNSON & JOHNSON 0.22% 41,165 0% 0.23% $1,267,059

Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 11,391,805 $349,891,420 +$8,387,255 $30.78 67
2025 Q3 9,484,049 $154,014,949 +$47,780,824 $16.24 56
2025 Q2 6,818,719 $60,295,418 +$60,292,297 $8.84 62